

## Engineering Conferences International ECI Digital Archives

---

Cell Culture Engineering XV

Proceedings

---

Spring 5-12-2016

# Understanding and controlling sialylation in a CHO fusion protein at lab and manufacturing scale using targeted omics techniques

Amanda Lewis

*Bristol-Myers Squibb Company, amanda.lewis@bms.com*

Nelly Aranibar

*Bristol-Myers Squibb Company*

William Croughan

*Bristol-Myers Squibb Company*

Nicholas Abu-Absi

*Bristol-Myers Squibb Company*

Bethanne Warrack

*Bristol-Myers Squibb Company*

*See next page for additional authors*

Follow this and additional works at: [http://dc.engconfintl.org/cellculture\\_xv](http://dc.engconfintl.org/cellculture_xv)



Part of the [Biomedical Engineering and Bioengineering Commons](#)

---

### Recommended Citation

Lewis, A.M., et al., The Use of 'Omics' Technology to Rationally Improve Industrial Mammalian Cell Line Performance. *Biotechnology and Bioengineering*, 2015: 10.1002/bit.25673

This Abstract is brought to you for free and open access by the Proceedings at ECI Digital Archives. It has been accepted for inclusion in Cell Culture Engineering XV by an authorized administrator of ECI Digital Archives. For more information, please contact [franco@bepress.com](mailto:franco@bepress.com).

---

**Authors**

Amanda Lewis, Nelly Aranibar, William Croughan, Nicholas Abu-Absi, Bethanne Warrack, Michael Borys, Michael Reily, and Zheng Jian Li

## UNDERSTANDING AND CONTROLLING SIALYATION IN A CHO FUSION PROTEIN AT LAB AND MANUFACTURING SCALE USING TARGETED OMICS TECHNIQUES

Amanda M. Lewis, Bristol-Myers Squibb Company  
amanda.lewis@bms.com

Nelly Aranibar, Bristol-Myers Squibb Company  
William D. Croughan, Bristol-Myers Squibb Company  
Nicholas R. Abu-Absi, Bristol-Myers Squibb Company  
Bethanne Warrack, Bristol-Myers Squibb Company  
Michael C. Borys, Bristol-Myers Squibb Company  
Michael D. Reily, Bristol-Myers Squibb Company  
Zheng Jian Li, Bristol-Myers Squibb Company

**Key Words:** glycosylation, N-acetylneuraminic acid, metabolomics, transcriptomics, CHO fusion protein

Biologics, including antibodies, hormones and cytokines, represent an increasingly important class of therapeutics, with 7 of the 10 top selling drugs from 2013 in this class. The glycosylation distribution of these proteins is an important characteristic that can impact biological activity, circulatory half-life, and immunogenicity. One property that affects glycoproteins is the terminal addition of N-acetylneuraminic acid (sialic acid) to glycosylation chains. Despite the importance of glycosylation in many therapeutic proteins, limited information is available to date linking process parameters to changes in glycosylation distribution. The majority of the work that has been done is limited to a small number of proteins (such as interferon gamma) and small scale systems (shake flasks and bench top bioreactors). Although this work represents a useful starting point, glycosylation is a parameter that is known to be influenced by production scale.

Here we examine a glycosylated CHO fusion protein for which sialylation level is known to impact protein quality. Variation in this parameter was observed across pilot and manufacturing scale batches. In order to better understand and control the biological source of the variation in the process, we employed metabolomic and transcriptomic methods, and successfully identified metabolic biomarkers, such as extracellular mannose, for sialylation level. Additional studies demonstrated that changes to sugar metabolism were contributing to a build-up of intermediates and inhibition of glycan sialylation, thereby identifying the biological source of variation in the process. As a result of these studies, we evaluated the impact of process modifications including feed composition and gassing to enable consistent control of sialylation profiles.

This work represents a novel contribution to the field. We examine sialylation control of a CHO fusion protein at laboratory and manufacturing scale. Furthermore, we combine 'Omics techniques with bioprocess and analytical data to achieve a more detailed understanding of cell expression and metabolism [1], and leverage this understanding to refine the process and control a quality attribute. Finally, this approach can be generalized beyond this specific process and applied to additional cell lines where undesired process variation is observed.

1. Lewis, A.M., et al., *The Use of 'Omics Technology to Rationally Improve Industrial Mammalian Cell Line Performance*. Biotechnology and Bioengineering, 2015: 10.1002/bit.25673